Fortress Biotech, INC. (FBIOP) — SEC Filings

Overview

Fortress Biotech, INC. (FBIOP) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a S-1 filed on Dec 16, 2025: Fortress Biotech, Inc. (FBIOP) filed an S-1 to register 600,000 shares of common stock for resale by selling stockholders, specifically Oaktree Fund Administration, LLC and its affiliates. These shares are issuable upon the exercise of warrants granted on December 12, 2025, with an exercise price of

Sentiment Summary

Across 44 filings, the sentiment breakdown is: 41 neutral, 3 mixed. The dominant filing sentiment for Fortress Biotech, INC. is neutral.

Filing Type Overview

Fortress Biotech, INC. (FBIOP) has filed 2 S-1, 23 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 7 SC 13D/A, 1 SC 13G, 1 SC 13G/A with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (44)

• Fortress Biotech Registers 600K Shares for Oaktree Resale — S-1 · Dec 16, 2025 Risk: medium
  Fortress Biotech, Inc. (FBIOP) filed an S-1 to register 600,000 shares of common stock for resale by selling stockholders, specifically Oaktree Fund Administrat
• Fortress Biotech Files 8-K — 8-K · Dec 15, 2025 Risk: low
  Fortress Biotech, Inc. filed an 8-K on December 15, 2025, reporting on other events and financial statements. The filing details the company's incorporation in
• 8-K Filing — 8-K · Nov 17, 2025
• Fortress Biotech Swings to Profit on Revenue Growth, R&D Cuts — 10-Q · Nov 14, 2025 Risk: medium
  Fortress Biotech, Inc. reported a significant turnaround in its financial performance for the three and nine months ended September 30, 2025. For the three-mont
• Fortress Biotech Files 8-K on Oct 1, 2025 — 8-K · Oct 1, 2025 Risk: low
  Fortress Biotech, Inc. filed an 8-K on October 1, 2025, reporting other events and financial statements. The company, incorporated in Delaware, is in the pharma
• Fortress Biotech Swings to Profit on Subsidiary Deconsolidation Gain — 10-Q · Aug 14, 2025 Risk: high
  Fortress Biotech, Inc. reported a significant turnaround in net income attributable to Fortress, reaching $15.486 million for the three months ended June 30, 20
• Fortress Biotech Files 8-K with Office and Name Change Info — 8-K · Jul 16, 2025 Risk: low
  On July 16, 2025, Fortress Biotech, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 1111 Kane Concourse,
• Fortress Biotech Reports on Shareholder Vote — 8-K · Jun 23, 2025 Risk: low
  Fortress Biotech, Inc. filed an 8-K on June 23, 2025, reporting on matters submitted to a vote of security holders on June 17, 2025. The filing pertains to thei
• Fortress Biotech Completes Asset Acquisition/Disposition — 8-K · Jun 5, 2025 Risk: medium
  Fortress Biotech, Inc. filed an 8-K on May 30, 2025, reporting the completion of an acquisition or disposition of assets. The filing also includes financial sta
• Fortress Biotech Files Q1 2025 10-Q — 10-Q · May 15, 2025 Risk: medium
  Fortress Biotech, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported total assets of $34.3 million and total liabilities of $2.8 mil
• Fortress Biotech (FBIO) DEF 14A: Executive Compensation Details — DEF 14A · Apr 28, 2025 Risk: medium
  Fortress Biotech, Inc. (FBIO) filed a DEF 14A on April 28, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing inclu
• Fortress Biotech Announces Executive and Director Changes — 8-K · Apr 16, 2025 Risk: medium
  Fortress Biotech, Inc. announced on April 15, 2025, changes in its board of directors and executive officers. The company also disclosed information regarding c
• Fortress Biotech Files 2024 Annual Report — 10-K · Mar 31, 2025 Risk: medium
  Fortress Biotech, Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company, operating in pharmaceutical preparations, reported key financia
• Fortress Biotech Enters Material Definitive Agreement — 8-K · Mar 10, 2025 Risk: medium
  On March 9, 2025, Fortress Biotech, Inc. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive office
• Fortress Biotech Relocates HQ, Confirms Fiscal Year End — 8-K · Jan 16, 2025 Risk: low
  On January 16, 2025, Fortress Biotech, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 1111 Kane Concour
• Fortress Biotech Files 8-K — 8-K · Jan 6, 2025 Risk: medium
  Fortress Biotech, Inc. filed an 8-K on January 6, 2025, reporting an "Other Event." The filing does not contain specific details about the event, dollar amounts
• Fortress Biotech Files 8-K — 8-K · Dec 16, 2024 Risk: low
  Fortress Biotech, Inc. filed an 8-K on December 13, 2024, reporting an "Other Event." The filing does not contain specific details about the event, dollar amoun
• Fortress Biotech Amends Avenue Therapeutics Filing — SC 13D/A · Nov 15, 2024 Risk: medium
  Fortress Biotech, Inc. filed an amendment (Amendment No. 5) to its Schedule 13D on November 15, 2024, regarding its holdings in Avenue Therapeutics, Inc. The fi
• Fortress Biotech Q3 2024: Assets $19.7M, Liabilities $7.2M — 10-Q · Nov 14, 2024 Risk: medium
  Fortress Biotech, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported total assets of $19.7 million and total liabilities of $7.2
• Fortress Biotech Files 8-K Report — 8-K · Nov 4, 2024 Risk: low
  On November 4, 2024, Fortress Biotech, Inc. filed an 8-K report. The filing indicates that the company is incorporated in Delaware and its principal executive o
• SC 13G Filing — SC 13G · Oct 25, 2024
• Fortress Biotech Files SC 13D/A for Checkpoint Therapeutics — SC 13D/A · Oct 1, 2024 Risk: medium
  Fortress Biotech, Inc. has filed an amendment (Amendment No. 8) to its Schedule 13D concerning Checkpoint Therapeutics, Inc. The filing, dated October 1, 2024,
• Fortress Biotech Files S-1 Registration — S-1 · Sep 27, 2024 Risk: medium
  Fortress Biotech, Inc. filed an S-1 registration statement on September 27, 2024, to register securities under the Securities Act of 1933. The company, incorpor
• Rosenwald Amends Fortress Biotech Stake Filing — SC 13D/A · Sep 25, 2024 Risk: medium
  Lindsay A. Rosenwald, M.D. has filed an amendment (Amendment No. 4) to Schedule 13D for Fortress Biotech, Inc. on September 25, 2024. This filing relates to the
• Fortress Biotech Enters Material Agreement, Reports Equity Sales — 8-K · Sep 23, 2024 Risk: medium
  Fortress Biotech, Inc. announced on September 19, 2024, that it entered into a material definitive agreement. The company also reported on unregistered sales of
• Fortress Biotech Q2 2024: Assets $225.9M, Liabilities $15.1M — 10-Q · Aug 13, 2024 Risk: medium
  Fortress Biotech, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported total assets of $225.9 million and total liabilities of $15.1 mi
• Fortress Biotech Files 8-K on Agreements and Equity Sales — 8-K · Jul 25, 2024 Risk: medium
  On July 25, 2024, Fortress Biotech, Inc. filed an 8-K detailing several significant events. These include entering into and terminating material definitive agre
• Fortress Biotech Enters Material Definitive Agreement — 8-K · Jul 19, 2024 Risk: medium
  On July 15, 2024, Fortress Biotech, Inc. entered into a material definitive agreement. The filing does not provide specific details on the nature of the agreeme
• Fortress Biotech Files 8-K — 8-K · Jul 5, 2024 Risk: low
  On July 5, 2024, Fortress Biotech, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific n
• Fortress Biotech Amends Mustang Bio Stake Filing — SC 13D/A · Jun 28, 2024 Risk: medium
  Fortress Biotech, Inc. filed an amendment (No. 3) to its Schedule 13D on June 28, 2024, regarding its holdings in Mustang Bio, Inc. The filing indicates a chang
• Fortress Biotech Files 8-K on Equity Sale — 8-K · Jun 28, 2024 Risk: medium
  On June 27, 2024, Fortress Biotech, Inc. filed an 8-K report detailing the unregistered sale of equity securities. The company, incorporated in Delaware, issued
• Fortress Biotech Files 8-K for Corporate Changes — 8-K · Jun 25, 2024 Risk: low
  Fortress Biotech, Inc. filed an 8-K on June 25, 2024, reporting a change in its corporate structure or bylaws as of June 19, 2024. The filing also includes fina
• Fortress Biotech Sells Fortress Vision for $15M — 8-K · May 29, 2024 Risk: medium
  Fortress Biotech, Inc. announced on May 23, 2024, a definitive agreement to sell its subsidiary, Fortress Vision, to NovaSight Ltd. for $15 million in cash. The
• Fortress Biotech Files SC 13D/A Amendment — SC 13D/A · May 17, 2024 Risk: medium
  Fortress Biotech, Inc. filed an amendment (No. 7) to its Schedule 13D on May 17, 2024, regarding its beneficial ownership of Checkpoint Therapeutics, Inc. commo
• Fortress Biotech Files 8-K on Financials — 8-K · May 15, 2024 Risk: low
  Fortress Biotech, Inc. filed an 8-K on May 15, 2024, reporting on its results of operations and financial condition. The filing includes financial statements an
• Fortress Biotech, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 15, 2024 Risk: medium
  Fortress Biotech, Inc. (FBIOP) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Fortress Biotech, Inc. filed a 10-Q for the period ending March 31,
• Fortress Biotech Amends Filing for Avenue Therapeutics — SC 13D/A · Apr 17, 2024 Risk: medium
  Fortress Biotech, Inc. has filed an amendment (No. 4) to its Schedule 13D concerning Avenue Therapeutics, Inc. as of April 17, 2024. Fortress Biotech, Inc. is l
• Fortress Biotech Announces 2024 Annual Meeting of Stockholders — DEF 14A · Apr 5, 2024 Risk: low
  Fortress Biotech, Inc. (FBIOP) filed a Proxy Statement (DEF 14A) with the SEC on April 5, 2024. Annual Meeting scheduled for May 23, 2024, conducted virtually.
• Fortress Biotech Files 8-K on Financials — 8-K · Mar 28, 2024 Risk: low
  Fortress Biotech, Inc. filed an 8-K on March 28, 2024, reporting on its results of operations and financial condition. The filing includes financial statements
• Fortress Biotech, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 28, 2024 Risk: medium
  Fortress Biotech, Inc. (FBIOP) filed a Annual Report (10-K) with the SEC on March 28, 2024. Fortress Biotech, Inc. filed its 2023 Form 10-K on March 28, 2024. T
• Fortress Biotech Amends SEC Filing for Checkpoint Therapeutics — SC 13D/A · Mar 22, 2024 Risk: medium
  Fortress Biotech, Inc. filed an amendment (No. 6) to its Schedule 13D on March 22, 2024, regarding its holdings in Checkpoint Therapeutics, Inc. The filing indi
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• Fortress Biotech 8-K: Officer/Director Changes & Comp Arrangements — 8-K · Jan 26, 2024
  Fortress Biotech, Inc. filed an 8-K on January 26, 2024, reporting an event that occurred on January 25, 2024, related to the departure or election of directors
• Fortress Biotech Enters Material Definitive Agreement — 8-K · Jan 3, 2024
  Fortress Biotech, Inc. filed an 8-K on January 3, 2024, reporting an event on December 29, 2023, related to an entry into a material definitive agreement. The f

Risk Profile

Risk Assessment: Of FBIOP's 39 recent filings, 1 were flagged as high-risk, 26 as medium-risk, and 12 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Fortress Biotech, INC.'s most recent 10-Q filing (Nov 14, 2025):

• Revenue: $17,631,000
• Net Income: $5,850,000
• EPS: N/A
• Debt-to-Equity: N/A
• Cash Position: $86,218,000
• Operating Margin: N/A
• Total Assets: $181,407,000
• Total Debt: $116,222,000

Key Executives

• Lindsay A. Rosenwald, M.D.

Industry Context

Fortress Biotech operates in the biopharmaceutical sector, focusing on acquiring and advancing clinical-stage assets. This strategy involves developing drug candidates through various stages, with potential revenue generated from product sales, equity holdings in partner companies, and royalties. The industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles, but also offers substantial rewards through successful drug development and market entry.

Top Tags

sec-filing (11) · ownership-change (5) · 8-K (4) · filing (4) · material-agreement (4) · schedule-13d (4) · Biotechnology (3) · Pharmaceuticals (3) · pharmaceuticals (3) · corporate-governance (3)

Key Numbers

• FBIO Stock Price: $2.94 — Last reported sale price on December 11, 2025, indicating market valuation.
• Warrant Exercise Price: $2.62 — Price at which Oaktree can acquire shares, below current market price.
• Shares Registered for Resale: 600,000 — Potential increase in market float from Oaktree's warrant exercise.
• Shares Outstanding: 31,037,937 — Common stock outstanding as of December 11, 2025, before warrant exercise.
• Shares Outstanding (Post-Warrant): 31,637,937 — Total shares outstanding assuming full exercise of Oaktree's warrants.
• Warrant Grant Date: December 12, 2025 — Date of the First Amendment to Credit Agreement and warrant issuance.
• Warrant Expiration Date: July 25, 2031 — Long-term window for Oaktree to exercise its warrants.
• Checkpoint Acquisition Date: May 2025 — Date Checkpoint Therapeutics was acquired by Sun Pharma.
• Baergic Acquisition Date: November 2025 — Date Baergic Bio was acquired by Axsome Therapeutics.
• Net income attributable to Fortress (Q3 2025): $5.85M — Significant improvement from a $12.87M net loss in Q3 2024
• Net income attributable to Fortress (YTD Sep 2025): $10.75M — Reversal from a $39.23M net loss in YTD Sep 2024
• Net revenue (Q3 2025): $17.63M — 20.5% increase from $14.63M in Q3 2024
• Net revenue (YTD Sep 2025): $47.18M — Increase from $42.56M in YTD Sep 2024
• Research and development expenses (Q3 2025): $0.21M — Dramatic decrease from $9.45M in Q3 2024
• Research and development expenses (YTD Sep 2025): $12.27M — Significant decrease from $46.94M in YTD Sep 2024

Related Companies

FBIO · DERM · MBIO · ATXI · CKPT · NSGT · FBRX

Frequently Asked Questions